Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.79 USD
-0.06 (-2.11%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $2.79 0.00 (0.00%) 5:10 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.79 USD
-0.06 (-2.11%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $2.79 0.00 (0.00%) 5:10 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
Sarepta Stock Up Almost 40% This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks
by Nalak Das
A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AYTU) Outperforming Other Medical Stocks This Year?
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aytu Bioscience, Inc. (AYTU) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aytu Bioscience, Inc. (AYTU) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).